Key points:

1. SEQUOIA Update: Discover how this study led to the approval of Zanubrutinib in the frontline setting and its impressive progression-free survival rates compared to traditional chemotherapy.
2. AMPLIFY Study: Learn about the exciting combination of Acalabrutinib with Venetoclax and Obinutuzumab, and how it may pave the way for the first oral doublet/triplet combination approval in the U.S.
3. Ongoing Trials: We touch on the CELESTIAL TN-CLL trial and the promising combination of Zanubrutinib with Sonrotoclax, a new BCL-2 inhibitor.
In this episode of the Oncology Brothers podcast, we dived into the highlights from ASH 2024, focusing specifically on Chronic Lymphocytic Leukemia (CLL). Drs. Rahul & Rohit Gosain were joined by Dr. John Allan from the New York Presbyterian Hospital to discuss three pivotal studies that are shaping the landscape of CLL treatment.
We started with the SEQUOIA study, which led to the approval of Zanubrutinib as a frontline treatment. Dr. Allan explained the study's design, emphasizing its randomized control against bendamustine-rituximab and the impressive progression-free survival (PFS) results that favor Zanubrutinib. We also touch on the toxicity profiles of various BTK inhibitors, highlighting the differences and considerations when choosing between them.
Next, we explored the AMPLIFY study, which investigates the combination of Acalabrutinib with Venetoclax and Obinutuzumab. Dr. Allan shared insights on the study's design and findings, noting the improved PFS and the potential for this combination to become a new standard of care, despite the associated toxicity.
We also discussed the ongoing trial of Zanubrutinib combined with Sonrotoclax, a new BCL-2 inhibitor, which shows promising early results in treatment-naive patients. Dr. Allan expresses optimism about this combination and its potential to offer an all-oral therapy option.
Finally, we address the role of CAR-T therapy in CLL, particularly for patients who have progressed through multiple lines of treatment. Dr. Allan highlights the challenges and logistics involved in administering CAR-T, as well as the importance of collaboration between community oncologists and specialized centers.
In summary, this episode provides a comprehensive overview of the latest advancements in CLL treatment, emphasizing the importance of balancing efficacy and toxicity in our therapeutic choices. We encourage our listeners to stay tuned for more discussions on ASH and SABCS 2024. Thank you for joining us on this journey through the evolving landscape of oncology!